Reports - Cancer Biologics Market
HealthcareCancer Biologics Market
Cancer Biologics Market Size, Growth Projections And Insights 2025-2035 by Drug Class (Monoclonal Antibodies, Cancer Growth Inhibitors, Vaccines, Recombinants Proteins, CAR-T Cells, Angiogenesis Inhibitors, Interleukins (IL), Interferons (IFN), Gene Therapy, Other Drug Classes) by Application (Blood Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Gastric Cancer, Ovarian Cancer, Skin Cancer, Liver Cancer, Other Applications) by End Use (Hospitals, Cancer Center, Academics & Research Institutes) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Industry Leaders Trust Us For Actionable Intelligence
Table of Contents
Chapter 1 Executive Dashboard
1. Strategic Imperatives
Chapter 2 Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Chapter 3 Global Cancer Biologics Market - Segment Analysis
1. Overview
2. Global Cancer Biologics Market, 2021 - 2035 (USD Million)
3. Global Cancer Biologics Market - by Drug Class
3.1. By Monoclonal Antibodies
3.2. By Cancer Growth Inhibitors
3.3. By Vaccines
3.4. By Recombinants Proteins
3.5. By CAR-T Cells
3.6. By Angiogenesis Inhibitors
3.7. By Interleukins (IL)
3.8. By Interferons (IFN)
3.9. By Gene Therapy
3.10. By Other Drug Classes
4. Global Cancer Biologics Market - by Application
4.1. By Blood Cancer
4.2. By Lung Cancer
4.3. By Breast Cancer
4.4. By Colorectal Cancer
4.5. By Prostate Cancer
4.6. By Gastric Cancer
4.7. By Ovarian Cancer
4.8. By Skin Cancer
4.9. By Liver Cancer
4.10. By Other Applications
5. Global Cancer Biologics Market - by End Use
5.1. By Hospitals
5.2. By Cancer Center
5.3. By Academics & Research Institutes
6. Global Cancer Biologics Market - by region
6.1. North America
6.2. Europe
6.3. Asia Pacific
6.4. Latin America
6.5. Middle East & Africa
7. Market comparative analysis
Chapter 4 North America Cancer Biologics Market - Segment Analysis
1. Overview
2. North America Cancer Biologics Market, 2021 - 2035 (USD Million)
3. North America Cancer Biologics Market - by Drug Class
3.1. By Monoclonal Antibodies
3.2. By Cancer Growth Inhibitors
3.3. By Vaccines
3.4. By Recombinants Proteins
3.5. By CAR-T Cells
3.6. By Angiogenesis Inhibitors
3.7. By Interleukins (IL)
3.8. By Interferons (IFN)
3.9. By Gene Therapy
3.10. By Other Drug Classes
4. North America Cancer Biologics Market - by Application
4.1. By Blood Cancer
4.2. By Lung Cancer
4.3. By Breast Cancer
4.4. By Colorectal Cancer
4.5. By Prostate Cancer
4.6. By Gastric Cancer
4.7. By Ovarian Cancer
4.8. By Skin Cancer
4.9. By Liver Cancer
4.10. By Other Applications
5. North America Cancer Biologics Market - by End Use
5.1. By Hospitals
5.2. By Cancer Center
5.3. By Academics & Research Institutes
Chapter 5 Europe Cancer Biologics Market - Segment Analysis
1. Overview
2. Europe Cancer Biologics Market, 2021 - 2035 (USD Million)
3. Europe Cancer Biologics Market - by Drug Class
3.1. By Monoclonal Antibodies
3.2. By Cancer Growth Inhibitors
3.3. By Vaccines
3.4. By Recombinants Proteins
3.5. By CAR-T Cells
3.6. By Angiogenesis Inhibitors
3.7. By Interleukins (IL)
3.8. By Interferons (IFN)
3.9. By Gene Therapy
3.10. By Other Drug Classes
4. Europe Cancer Biologics Market - by Application
4.1. By Blood Cancer
4.2. By Lung Cancer
4.3. By Breast Cancer
4.4. By Colorectal Cancer
4.5. By Prostate Cancer
4.6. By Gastric Cancer
4.7. By Ovarian Cancer
4.8. By Skin Cancer
4.9. By Liver Cancer
4.10. By Other Applications
5. Europe Cancer Biologics Market - by End Use
5.1. By Hospitals
5.2. By Cancer Center
5.3. By Academics & Research Institutes
Chapter 6 Asia Pacific Cancer Biologics Market - Segment Analysis
1. Overview
2. Asia Pacific Cancer Biologics Market, 2021 - 2035 (USD Million)
3. Asia Pacific Cancer Biologics Market - by Drug Class
3.1. By Monoclonal Antibodies
3.2. By Cancer Growth Inhibitors
3.3. By Vaccines
3.4. By Recombinants Proteins
3.5. By CAR-T Cells
3.6. By Angiogenesis Inhibitors
3.7. By Interleukins (IL)
3.8. By Interferons (IFN)
3.9. By Gene Therapy
3.10. By Other Drug Classes
4. Asia Pacific Cancer Biologics Market - by Application
4.1. By Blood Cancer
4.2. By Lung Cancer
4.3. By Breast Cancer
4.4. By Colorectal Cancer
4.5. By Prostate Cancer
4.6. By Gastric Cancer
4.7. By Ovarian Cancer
4.8. By Skin Cancer
4.9. By Liver Cancer
4.10. By Other Applications
5. Asia Pacific Cancer Biologics Market - by End Use
5.1. By Hospitals
5.2. By Cancer Center
5.3. By Academics & Research Institutes
Chapter 7 Latin America Cancer Biologics Market - Segment Analysis
1. Overview
2. Latin America Cancer Biologics Market, 2021 - 2035 (USD Million)
3. Latin America Cancer Biologics Market - by Drug Class
3.1. By Monoclonal Antibodies
3.2. By Cancer Growth Inhibitors
3.3. By Vaccines
3.4. By Recombinants Proteins
3.5. By CAR-T Cells
3.6. By Angiogenesis Inhibitors
3.7. By Interleukins (IL)
3.8. By Interferons (IFN)
3.9. By Gene Therapy
3.10. By Other Drug Classes
4. Latin America Cancer Biologics Market - by Application
4.1. By Blood Cancer
4.2. By Lung Cancer
4.3. By Breast Cancer
4.4. By Colorectal Cancer
4.5. By Prostate Cancer
4.6. By Gastric Cancer
4.7. By Ovarian Cancer
4.8. By Skin Cancer
4.9. By Liver Cancer
4.10. By Other Applications
5. Latin America Cancer Biologics Market - by End Use
5.1. By Hospitals
5.2. By Cancer Center
5.3. By Academics & Research Institutes
Chapter 8 Middle East & Africa Cancer Biologics Market - Segment Analysis
1. Overview
2. Middle East & Africa Cancer Biologics Market, 2021 - 2035 (USD Million)
3. Middle East & Africa Cancer Biologics Market - by Drug Class
3.1. By Monoclonal Antibodies
3.2. By Cancer Growth Inhibitors
3.3. By Vaccines
3.4. By Recombinants Proteins
3.5. By CAR-T Cells
3.6. By Angiogenesis Inhibitors
3.7. By Interleukins (IL)
3.8. By Interferons (IFN)
3.9. By Gene Therapy
3.10. By Other Drug Classes
4. Middle East & Africa Cancer Biologics Market - by Application
4.1. By Blood Cancer
4.2. By Lung Cancer
4.3. By Breast Cancer
4.4. By Colorectal Cancer
4.5. By Prostate Cancer
4.6. By Gastric Cancer
4.7. By Ovarian Cancer
4.8. By Skin Cancer
4.9. By Liver Cancer
4.10. By Other Applications
5. Middle East & Africa Cancer Biologics Market - by End Use
5.1. By Hospitals
5.2. By Cancer Center
5.3. By Academics & Research Institutes
Chapter 9 Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
Chapter 10 COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Chapter 11 Marketing Strategy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Chapter 12 Competitive Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Chapter 13 Company Profiles
1. Abbott Laboratories (U.S.)
2. Angel Pharmaceuticals (China)
3. Amgen Inc. (U.S.)
4. AstraZeneca (UK)
5. BioNTech (Germany)
6. Bristol-Mayer Squibb Company (U.S.)
7. Dr. Reddys Laboratories (India)
8. Duality Biologics (China)
9. Eli Lilly and Company (U.S.)
10. F. Hoffmann-La Roche Ltd. (Switzerland)
Chapter 14 Key Primary Respondents - VERBATIM
Chapter 15 Discussion Guide
Chapter 16 Customization Offered
Chapter 17 Annexure
Chapter 18 List of Figures
Chapter 19 List of Tables
Chapter 20 List of Abbreviations
FAQ‘s
Related Reports
Contact
Toll Free Number+1 (877) 462-2282
© 2025 Vantage Market Research. All right reserved
Secured By